BCL2 and neoplasm: Interestingly, the enforced expression of BCL-2 in these lymphoma cells did not sensitise them to the BCL-2 inhibitor venetoclax (Fig. 1d), likely because these tumour cells did not develop under conditions of high BCL-2 expression and therefore do not depend on BCL-2 expression for continued survival.